Filing Flows › Jaguar Health (JAGX) › Q2 2026 › vs Q2 2025
Jaguar Health (JAGX) Q2 2026 vs Q2 2025 (year over year)
Jaguar Health's revenue fell $1.8M (-59%) from $3.0M in Q2 2025 to $1.2M in Q2 2026. The biggest changes: Product −$1.8M (-60%); License +$0 (0%).
Jaguar Health, Q2 2026: revenue $1.2M (-59% year over year), operating margin -620.2%, net loss $12.8M, operating cash flow −$5.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $1.2M | $2.9M | −$1.8M | -60% |
| License | $43K | $43K | $0 | 0% |
| Revenue | $1.2M | $3.0M | −$1.8M | -59% |
| Net loss | $12.8M | $10.6M | $2.2M | +21% |
| Costs & expenses | $14.0M | $13.5M | $488K | +4% |
| Operating costs | $8.8M | $11.0M | −$2.2M | -20% |
| Interest & other, net | $5.2M | $2.6M | $2.7M | +104% |
| Cost of revenue | $1.0M | $527K | $504K | +96% |
| Research & development | $3.3M | $3.3M | $71K | +2% |
| Sales & marketing | $5K | $2.5M | −$2.5M | -100% |
| General & admin | $4.5M | $4.7M | −$277K | -6% |
| Operating cash sources | $12.8M | $10.6M | $2.2M | +21% |
| Depreciation & amortization | $473K | $478K | −$5K | -1% |
| Share-based compensation | $171K | $279K | −$108K | -39% |
| Working capital & other | $6.8M | $3.6M | $3.2M | +89% |
| Cash used in operations | $5.3M | $6.2M | −$857K | -14% |
| Net loss absorbed | $12.8M | $10.6M | $2.2M | +21% |
Questions
How much did Jaguar Health's revenue grow year over year in Q2 2026?
Jaguar Health's revenue fell $1.8M (-59%) from $3.0M in Q2 2025 to $1.2M in Q2 2026.
What drove Jaguar Health's revenue change in Q2 2026?
Product −$1.8M (-60%); License +$0 (0%).